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The prevalence of polycystic ovaries (PCO) and polycystic ovary syndrome (PCOS) in the general population is approximately
20 and 10%, respectively, and published studies suggest a similar prevalence in women with epilepsy. These data do not suggest
that epilepsy is associated with a higher prevalence of the condition, and it would appear that the background prevalence of PCO
and PCOS is the same as in the general population.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders in the general population
and as reproductive endocrine disorders are common
in women with epilepsy, it is of no surprise that PCOS
has been commonly observed in women with epilepsy.
Women with epilepsy have significantly reduced fer-
tility rates compared to the general population1 and
it has been shown that both epilepsy and its treat-
ment can alter menstrual and fertility cycles2. When
treating women of childbearing age with epilepsy, it
is therefore important to consider the effect of the
anti-epileptic drugs (AEDs) on reproductive health, as
well as considering efficacy and tolerability.
Although several studies have proposed the possibil-
ity of a causal relationship between valproate and the
increased occurrence of polycystic ovaries (PCO) and
hyperandrogenism3–5, these studies have been criti-
cised for their retrospective design, and the findings
contradicted by more recent studies. Due to the con-
troversy in the area of epilepsy and PCOS, this review
aims to outline current evidence linking epilepsy and
AEDs to PCOS.
PCO
PCO are recognised with pelvic ultrasound as this
provides a non-invasive method of assessing the mor-
phological appearance of the ovary. They are char-
acterised by the presence of multiple follicular cysts
(10 or more), 2–8 mm in diameter, distributed either
peripherally around a dense core of stroma or scat-
tered throughout an increased amount of stroma6. PCO
are generally enlarged and are initially recognised in
puberty during the initiation of follicular activity at
menarche7. Ultrasound evaluation has revealed the
prevalence of PCO in the general female population
to be approximately 20%8–11, with a higher preva-
lence being observed in selected populations. They
may not be associated with any hormonal or clini-
cal abnormalities, but the most common feature is er-
ratic or infrequent ovulation giving rise to menstrual
irregularity. In a study of 173 women with anovu-
lation or hirsutism, PCO has been identified in 26%
of women with amenorrhoea, 87% of women with
oligomenorrhoea and 92% of women with idiopathic
hirsutism6. The typical features of PCO are shown in
Table 1.
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Table 1: Typical features of polycystic ovaries.
Anatomical features Clinical features Endocrine features
Multiple (≥10) cysts measuring 2–8 mm in diameter Menstrual abnormalitiesa Normal levels of luteinizing hormone
Peripherally located but can be disseminated Non-hirsute Normal levels of testosterone
Enlarged ovary with increased ovarian stroma Non-obese
a 95% have an irregular menstrual cycle.
PCOS
PCOS is one of the most common reproductive en-
docrine disorders, with heterogeneous clinical and
biochemical features, and is the most frequent cause
of anovulation and hirsutism7. PCOS was first de-
scribed by Stein and Leventhal in 1935, who presented
a report of seven women with menstrual irregularity
that had undergone laparotomy and bilateral ovarian
wedge resection13. In this study, PCO were charac-
terised histologically and found to be associated with
amenorrhoea, obesity and hirsutism. Histological ex-
amination revealed the presence of bilateral sclerotic
ovaries. Even in this early series of patients, the het-
erogeneity of clinical symptoms can be observed;
although all patients had a history of irregular menses,
only three women were obese and only four were
hirsute.
Clinical symptoms of PCOS include obesity and/or
hirsutism, which are seen in 40–50%14, 15, and men-
strual disorders, which are found in 30–70% of
women with PCOS9, 15. Endocrine abnormalities as-
sociated with PCOS are multiple (Table 2), however,
the most common findings include elevated luteiniz-
ing hormone levels, an increased luteinizing hor-
mone/follicle stimulating hormone ratio and elevated
serum androgen levels (free and total). Between 40
and 70% of women will have elevated luteinizing
hormone or androgen concentrations12, 16. Women
with PCOS also have lower sex hormone-binding
globulin than normal14, which leads to increased free
Table 2: Typical features of polycystic ovary syndrome.
Clinical features Endocrine features
Menstrual irregularity
(oligomenorrhoea or
amenorrhoea)
Increased luteinizing hormone
concentrations
Subfertility Increased luteinizing
hormone/follicle stimulating
hormone ratio
Obesity Increased androgen production
(testosterone, androstenedione)
Hirsutism and/or alopecia Normal follicle stimulating
hormone levels
Acne Abnormal lipid profile
Prolactin may be increased
Insulin resistance producing
hyperinsulinism
testosterone levels. It is interesting to note, however,
that ≥50% of women with PCO morphology have
normal luteinizing hormone and testosterone levels15
and that the clinical manifestation of androgen ex-
cess is not related to circulating androgen levels. It
is possible for a woman with excessive hirsutism to
have normal androgen concentrations, or conversely
a woman with no clinical signs of hirsutism to have
a raised serum androgen concentration.
The heterogeneity in the signs and symptoms of
PCOS has led to considerable controversy in this
area due to the difficulty in establishing a uniformly
accepted definition of PCOS. The absence of unify-
ing diagnostic criteria has plagued research into this
condition and many studies have been criticised for
the variable methods used to establish the diagnosis.
Many studies have defined PCOS using a limited num-
ber of features, such as finding clinical or endocrine
abnormalities in isolation. In the UK, it is now gener-
ally accepted that PCO detected by ultrasound scan,
in association with other clinical features (obesity,
hirsutism, menstrual irregularities or endocrine abnor-
malities) provides a sound diagnostic criterion15. The
prevalence of PCOS has been estimated to be 4%17.
This study defined PCOS as ovulatory dysfunction,
clinical evidence of hyperandrogenism and/or hyper-
androgenaemia and the exclusion of related disorders,
such as hyperprolactinaemia, thyroid disorders and
non-classic adrenal hyperplasia. This definition is
similar to the current UK definition as it excludes the
isolated finding of PCO.
There is a clear distinction between PCO and PCOS;
the morphologic appearance of PCO can exist without
any clinical signs of the syndrome. In fact, PCO can
be identified in girls as young as 6 months and are not
part of a disease7. Although the ovarian volume can
be reduced with the combined contraceptive pill, the
classic morphological features of PCO can still be ob-
served with an increased ovarian stroma and increased
numbers of follicular cysts.
The pathogenesis of PCOS is uncertain and it is un-
likely that a single mechanism could be applied to all
cases of PCOS. Evidence suggests that abnormalities
in the hypothalamic–pituitary–gonadal axis, hyperin-
sulinaemia, or local factors within the ovary, could all
play a role and environmental factors, such as weight
gain, may also induce the clinical expression of PCOS.
Additionally, there is strong evidence for a genetic
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basis for PCOS; PCO or clinical symptoms of PCOS
are present in 31–87% of first-degree relatives of pa-
tients with fully developed PCOS18. The exact mech-
anism of inheritance remains unclear19.
Under normal conditions the hypothalamic–pitui-
tary–gonadal axis controls the synthesis and concen-
trations of sex hormones, however, abnormalities in
the secretion of ovarian steroid and non-steroidal hor-
mones seem to affect feedback from the PCO to both
the pituitary and hypothalamus20. The disturbance of
this mechanism in women with PCOS results in the
formation of multiple small cysts.
PCOS is often associated with insulin resistance and
consequently hyperinsulinaemia, and although both
lean and obese women with PCOS show evidence of
decreased insulin sensitivity, insulin resistance is most
marked in the obese12. By suppressing the synthe-
sis of sex hormone-binding globulin, insulin increases
free androgen concentrations, subsequently increas-
ing the degree of hirsutism. The positive correlation
between insulin resistance and obesity means that in
some women with PCO, the clinical manifestation of
menstrual irregularity and hirsutism will only become
apparent if there is an increase in weight and associ-
ated metabolic changes.
There is a close association between weight gain
and an increase in anovulatory cycles and menstrual
irregularity21. The clinical expression of PCO can be
altered by ovarian suppression and changes in weight,
with weight loss being recommended as the first-line
therapeutic option for all women with obesity and
PCOS.
Epilepsy and PCOS
Women with epilepsy may be exposed to hormonal
imbalances that predispose them to the development
of PCOS. Reproductive endocrine disorders, such
as PCOS, are common in women with epilepsy22,
however, there is uncertainty as to whether it is
epilepsy or its treatment that predisposes to PCOS.
Both epilepsy and AEDs can have an effect on the
feedback loop of the hypothalamic–pituitary–gonadal
axis, which controls the synthesis and concentrations
of sex hormones23.
Some authors have suggested that epilepsy itself
may induce PCOS. Herzog et al.24 evaluated 50
women with partial seizures of the temporal lobe for
reproductive dysfunction. Of these women, 56% had
menstrual problems: 16% had amenorrhoea, 20% had
oligomenorrhoea and 20% had an abnormal menstrual
cycle interval. Of the women with menstrual dysfunc-
tion, 68% had reproductive endocrine disorders, 20%
of the total were diagnosed with PCOS. Although
these results confirm that reproductive dysfunction
is unusually common among women with temporal
lobe epilepsy, and suggest a possible association with
endocrine dysfunction, no significant relationship
was found between the use of AEDs and the occur-
rence of menstrual disorders. In this study, PCOS and
hypogonadotrophic hypogonadism occurred signifi-
cantly more often in women with epilepsy than in the
general female population. In another study, the same
group found that there was a significant difference be-
tween the EEG laterality distributions associated with
polycystic ovarian syndrome and those associated
with hypogonadotrophic hypogonadism25. Patients
with PCOS and untreated temporal lobe epilepsy had
predominantly left-sided interictal epileptiform dis-
charges in the EEG. This distribution differed signifi-
cantly from that of women with epilepsy who had no
reproductive endocrine disorders. The fact that PCOS
appears to be more frequent with left- than with
right-sided unilateral temporal lobe epileptogenic
discharges would also suggest that epilepsy induces
PCOS26.
Bilo et al.27 assessed the reproductive endocrine
function in 10 untreated epileptic women with nor-
mal menstrual cycles and in 5 normal controls and
found that the luteinizing hormone pulse frequency
was significantly higher in epileptic women, with a
consequent reduction of the luteinizing hormone in-
terpulse interval. The authors suggest that epilepsy
may interfere with the functional activity of the
gonadotropin-releasing hormone pulse generator and
hypothesise a possible relationship between luteiniz-
ing hormone hyperpulsatability of normally cycling
epileptic females and reproductive endocrine disor-
ders in epileptic women.
Reproductive endocrine disorders have also been re-
ported in women with primary generalised epilepsy28.
In this study of 20 women of childbearing age (17
of which were receiving AED therapy with valproate
and/or phenobarbital), 5 patients (25%) were diag-
nosed with reproductive endocrine disorders, 3 with
PCOS and 2 with hypothalamic ovarian failure. All
five patients with reproductive endocrine disorders had
long-standing menstrual irregularities.
AEDs and PCOS
Several studies have been conducted in order to deter-
mine the effects, if any, of AEDs on endocrine disor-
ders. Scandinavian studies have suggested that there is
a possible link between valproate and PCO3–5, how-
ever, the impact of AEDs on endocrine disorders is de-
bated. In the study conducted by Herzog et al.24, 6 of
the 10 women with PCOS were not receiving AEDs,
making it unlikely that the occurrence of PCOS was
related to the use of AEDs.
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The first Scandinavian study conducted by Isojärvi
et al.3 aimed to determine the frequency and types
of reproductive endocrine disorders in a large group
of women with epilepsy and to analyse the effects of
seizure type, seizure frequency and AED therapy on
the occurrence of these disorders. In this retrospec-
tive study, 238 women with epilepsy (mean age 33
years, range 18–45 years) were assessed and com-
pared to 51 healthy controls (mean age 35 years, range
22–45 years). Twenty-nine (12%) were treated with
valproate, 120 (50%) with carbamazepine, 12 (5%)
with valproate and carbamazepine, and 62 (26%) with
other medications, the mean duration of therapy was
9 years (range, 0–31); 15 (6%) were untreated. Men-
strual disturbances were found in 45% of women re-
ceiving valproate alone and 25% of those receiving
valproate in combination with carbamazepine, com-
pared to 19% of those receiving carbamazepine alone
and 13% of those receiving other medications. PCO
were found in 43% of women receiving valproate
(n = 12), 22% of women receiving carbamazepine
(n = 33), 50% of women receiving valproate and car-
bamazepine (n = 6), 11% of women receiving other
medications (n = 7) and in 5% of the normal control
group.
Although the results of this study suggest a link
between valproate therapy and PCOS, the study
design had several weaknesses. A major criticism
is that the retrospective nature of the study may
have resulted in selection bias: a significant selec-
tion among patients treated with valproate is most
probable, as the prevalence of valproate monother-
apy (12%) is far below the expected prevalence of
patients with idiopathic generalised epilepsy, who
are likely to be aggravated by CBZ treatment28.
Additionally, the study never distinguished clearly
between PCO and PCOS. By describing the number
of patients with PCO or elevated serum testosterone
concentrations, an increase in PCOS was implied, but
not actually demonstrated. Also, pre-treatment data
were not available and the prevalence of PCO and
menstrual disturbances was very low in the control
group.
The results of Isojärvi et al. have been widely
publicised. However, they are not supported by the
results of two recent studies22, 29. Bauer et al.22 con-
ducted a prospective study in 93 women with partial
epilepsy in order to determine whether PCOS is a
common finding in women treated with AEDs. In
this study the incidence of PCOS in patients treated
with valproate monotherapy (11.1%) was similar to
that for patients treated with carbamazepine (10%)
and also to that in patients receiving no medica-
tion (10.5%). This suggests that the manifestation of
PCOS in women with focal epilepsy is not related
to the administration of either valproate or carba-
mazepine22. In another study investigating the effects
of valproate, phenobarbital and carbamazepine on
sex hormones and luteal function, Murialdo et al.29
found that the prevalence of PCO did not differ sig-
nificantly between treatment groups. In a similar
study, the same group investigated menstrual cycle
and ovarian appearance in women with epilepsy re-
ceiving anti-epileptic therapy30. Eighty-three out of
101 women (36 with idiopathic generalised epilepsy
and 65 with partial epilepsy) treated with various
AEDs had abdominal ultrasound. PCO were found in
16.9% of patients (21.0% with idiopathic generalised
epilepsy and 14.5% with partial epilepsy). These
prevalences are the same as reported in the general
population8–11.
In a smaller, more recent study Isojärvi et al.4 evalu-
ated the association of obesity and hyperinsulinaemia
with valproate-related PCO and hyperandrogenism in
women with epilepsy. The authors found that obesity
was encountered in more than half of women receiv-
ing valproate, and proposed that weight gain is pro-
gressive and associated with low serum insulin-like
growth factor-binding protein 1 (IGFBP-1) levels,
which may lead to hyperandrogenism and PCO4.
This study may also have been biased by its retro-
spective nature and it should be noted that the trial
population was small, additionally the study never
distinguished clearly between PCO and PCOS. Dis-
continuation of VPA therapy leads to a reversal of
hyperinsulinaemia, hyperandrogenism, dyslipidaemia
and PCO in 12 women followed prospectively for
1 year5.
The theory that VPA induced weight gain leads
to increased insulin resistance with consequent hy-
perinsulinaemia and finally PCOS does not explain
why PCO and/or hyperandrogenism was also high
in lean VPA-treated patients. In an editorial com-
ment on this study, Herzog26 proposed that epilepsy
may induce PCOS and that PCOS is treated by
enzyme-inducing AEDs, but not by valproate, which
is an enzyme-inhibiting AED. By inducing hepatic
enzymes that reduce biologically active testosterone
in the serum and by increasing the binding and
metabolism of testosterone, some AEDs may inad-
vertently treat hyperandrogenism and thus PCOS,
while valproate therapy may not. SHBG is uniformly
elevated by chronic treatment with phenytoin, car-
bamazepine, primidone and phenobarbitone, but not
with valproate31.
Additionally, in a pilot study conducted in 22 women
with bipolar disorder, PCO-like changes were not ob-
served in women receiving divalproex (valproate) or
lithium32. Although this study was limited by small
patient numbers and by a cross-sectional design, the
results highlight the uncertainty as to the link between
valproate and PCO-like changes.
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DISCUSSION
Whether AEDs promote the development of PCO or
PCOS remains uncertain with conflicting evidence
from the published literature. With such a lack of
reliable and scientific data, it seems surprising that
recent guidelines2 have been published implying
that some AEDs should be avoided in women with
epilepsy. The evidence that was reviewed by these
guidelines was of medium to low validity (class II or
III) identifying the need for methodologically sound
research33. Surely, prospective studies, including
large numbers of epileptic women, are needed to es-
tablish whether any AED promotes the development
of PCO and PCOS. One such study is currently un-
derway in order to establish whether the link between
valproate and PCOS alleged by Isojärvi et al. can be
substantiated by a prospective, randomised controlled
trial in AED-naı¨ve patients34, 35. This study also aims
to investigate the anthropomorphic, ultrasonographic
and biochemical effects of lamotrigine and topiramate
on women with newly diagnosed epilepsy. Addition-
ally, a prospective study in pre-pubescent girls with
epilepsy, with a 10–15 year follow-up, is needed in
order to establish ovarian morphology changes during
puberty and to determine whether PCO are more com-
mon in women with epilepsy. This study would need
to use sound diagnostic techniques, including pelvic
ultrasonography.
There are few data on the association between
epilepsy and PCOS, and importantly no studies have
been conducted which include pre-treatment pelvic
ultrasound in order to assess the prevalence of PCO(S)
before AED treatment. Although studies conducted
in Scandinavia raise the issue of an association be-
tween valproate and PCO in women with epilepsy,
these studies have been criticised. The studies were
conducted in very small patient numbers of a se-
lected population, were retrospective, and did not
clearly distinguish between PCO morphology and
PCOS. The results of these studies have also been
contradicted by more recent findings.
Current evidence suggests that it is unlikely that
any AED can produce PCO from otherwise normal
ovaries and there are no data to contraindicate the
use of any AED in women with epilepsy. Although
valproate has been widely studied in this area, there
is no evidence to suggest that valproate should not
remain a first-line treatment option for women of
childbearing age with epilepsy. Although it is pos-
sible that weight gain may alter the endocrine, bio-
chemical and clinical features to produce the PCOS
in women who already had PCO, there is no con-
clusive evidence to support this and the mechanisms
are not fully understood. Further investigation is
needed.
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